No Data
No Data
Tiansheng Pharmaceutical's Isoniazid Tablets Pass Chinese Drug Regulator's Consistency Evaluation
Tiansheng Pharmaceuticals Group (002872.SZ): Isoniazid tablets pass generic drug consistency evaluation.
Gelonghui, October 14th | tiansheng pharmaceutical group (002872.SZ) announced that the company recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The "Isoniazid Tablets" of the company passed the evaluation of generic drug quality and efficacy consistency. Isoniazid inhibits the synthesis of the key component mycolic acid of bacterial cell walls. At therapeutic concentrations, isoniazid has a bactericidal effect on intracellular and extracellular mycobacterium tuberculosis in the growth and reproduction period. Isoniazid tablets are suitable for: (1) various types of tuberculosis sensitive to isoniazid in combination with other anti-tuberculosis drugs; (2) prevention of tuberculosis; (3) according to the country
ST Tiansheng: 2024 Semi-Annual Report
ST Tiansheng: 2024 Semi-Annual Report Summary
Tiansheng Pharmaceutical Group: 2024 Interim Performance Forecast
Tiansheng Pharmaceutical Group (002872.SZ): expected to lose RMB 40 million to 56 million in the first half of the year.
Tiansheng Pharmaceutical Group (002872.SZ) announced on July 9 that it is expected to suffer a loss of 400 to 560 million yuan in the first half of the year, with a non-net loss of 430 to 600 million yuan. The main reason for the company's performance loss during the reporting period is higher fixed costs such as fixed asset depreciation and labor costs.
No Data
No Data